Abstract:
The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.
Abstract:
The present invention provides an immune deficient mouse having a human prostate xenograft of locally advanced or metastatic prostate cancer and uses thereof.
Abstract:
The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.
Abstract:
The present invention provides an immune deficient mouse having a human prostate xenograft of locally advanced or metastatic prostate cancer and uses thereof.
Abstract:
The present invention provides an immune deficient mouse having a human prostate xenograft of locally advanced or metastatic prostate cancer and uses thereof.
Abstract:
The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.
Abstract:
The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors. The invention also provides a method for detecting a Prostate Stem Cell Antigen (PSCA) protein of bone (SEQ ID NO:2), comprising obtaining a sample; contacting the sample with an antibody that recognizes and binds the PSCA protein; and, detecting binding of the antibody with the PSCA protein in the sample.
Abstract translation:本发明提供了一种新的前列腺细胞表面抗原,其命名为前列腺干细胞抗原(PSCA),其在前列腺癌的所有阶段中广泛过表达,包括高级前列腺上皮内瘤变(PIN),雄激素依赖性和雄激素依赖性 前列腺肿瘤。 本发明还提供了一种用于检测骨的前列腺干细胞抗原(PSCA)蛋白质(SEQ ID NO:2)的方法,包括获得样品; 使样品与识别并结合PSCA蛋白的抗体接触; 并检测样品中抗体与PSCA蛋白的结合。
Abstract:
The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.
Abstract:
The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.
Abstract:
The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.